NanoEntek
NanoEntek is a privately-held South Korean biotechnology company that develops lab-on-a-chip MEMS/microfluidics instruments for automated cell counting, immunofluorescence diagnostics, blood safety testing, and — via its L'Oréal Cell BioPrint partnership — consumer beauty-tech skin analysis.
- Company typePrivate
- Founded2000
- HeadquartersSeoul, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What NanoEntek does
NanoEntek is a privately-held South Korean biotechnology company founded in 2000 and headquartered in Seoul that develops lab-on-a-chip instruments combining MEMS and microfluidics for biomedical analysis. Its portfolio spans automated cell counters (EVE and ADAM series), microfluidic immunofluorescence analyzers (FREND system), rapid diagnostic tests (BioTracer dengue and influenza), residual white blood cell counters for blood bank quality control (ADAM rWBC), CD34/CD3 stem cell and T-cell enumeration kits (ADAMII), a pipette-style electroporation system (ExTransfection), and disposable plastic hemocytometers (C-Chip and S-Chip). The company's installed base exceeds 10,000 automated cell counter devices globally, with 100+ cell therapy research institutes and companies using ADAM-MC products for CAR-T and stem cell manufacturing quality control.
NanoEntek's underlying technology designs microchannels on plastic or glass microfluid chips to control biofluid flow, enabling miniaturized assays with 20µL samples and high-throughput processing (48 samples in 3 minutes on EVE HT). Selected instruments offer optional 21 CFR Part 11 compliance for cGMP environments. In 2026 the company extended its technology into consumer applications through a Cell BioPrint partnership with L'Oréal, providing biomarker-based skin analysis embedded in Lancôme's Absolue Longevity MD skincare line.
Revenue is generated through a hybrid direct sales and global distributor model across wholly-owned operations in Seoul, Waltham MA, Martinsried Germany, and Beijing, serving cell therapy manufacturers, blood banks, clinical diagnostics laboratories, and — more recently — cosmetics and personal care brands. The revenue mix comprises one-time hardware instrument sales, recurring consumables and reagents (counting kits, staining reagents, assay cartridges), in vitro diagnostic test kits, and licensing royalties from the L'Oréal beauty-tech partnership. Customer concentration is distributed across diverse verticals, though the Lancôme relationship represents a notable consumer-brand anchor. Public financial disclosure is limited; the company is privately held with no disclosed funding rounds beyond a 2004 Shinhan Venture Investment.
NanoEntek firmographics
Firmographics- Name
- NanoEntek
- Legal name
- NanoEntek
- Website
- https://nanoentek.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- NanoEntek is a privately-held South Korean biotechnology company that develops lab-on-a-chip MEMS/microfluidics instruments for automated cell counting, immunofluorescence diagnostics, blood safety testing, and — via its L'Oréal Cell BioPrint partnership — consumer beauty-tech skin analysis.
- Ownership category
- akta.pro rank
NanoEntek industry classification
Industry- Product category
- Life Science Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
Keywords
Where NanoEntek is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices5 records
Markets served
NanoEntek business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales
Revenue model
- Automated Cell Counters and Analyzers: Sale of automated cell counting instruments including EVE series, ADAM series for life science research, cell therapy manufacturing, and clinical diagnostics. Revenue is one-time hardware sale with recurring consumables revenue.
- Consumables and Reagents: Recurring revenue from disposable products including counting kits, assay slides, staining reagents (AO/DAPI, PI), and control plates for their instrument platforms.
- In Vitro Diagnostic Tests: Sale of rapid diagnostic test products including Dengue NS1/IgG/IgM, COVID-19 tests, Influenza A&B, and immunoassay cartridges for the FREND system covering thyroid, cardiac, and other biomarkers.
- Licensing/Technology Partnerships: Revenue from licensing Cell BioPrint technology to L'Oréal for use in Lancôme's Absolue Longevity MD skincare line - represents new business model for cosmetic/beauty tech applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B enterprise pricing through direct sales and distribution network |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
NanoEntek product offering
Product offeringCore offering
NanoEntek designs and manufactures lab-on-a-chip instruments that combine MEMS and micro-fluidics for biomedical analysis. The company sells automated cell counters (EVE and ADAM series), a microfluidic immunofluorescence diagnostic analyzer (FREND), rapid diagnostic test kits (BioTracer), disposable plastic hemocytometers (C-Chip, S-Chip), live cell imaging systems (JuLI), and an electroporation system (ExTransfection), used by cell therapy manufacturers, blood banks, and clinical laboratories. The Cell BioPrint biomarker-based skin diagnostic technology was developed and licensed to L'Oréal for use in Lancôme's Absolue Longevity MD skincare line.
Product overview
NanoEntek is a Korean biotechnology company specializing in lab-on-a-chip technology that combines MEMS and micro-fluidics for biomedical analysis. The company offers a diverse product portfolio organized into several core platforms: (1) FREND™ System - a microfluidic immunofluorescence analyzer supporting multiple diagnostic test cartridges for thyroid, cardiac, infectious diseases (including COVID-19), and other biomarkers; (2) Automated Cell Counters (EVE™ and ADAM™ series) - high-throughput instruments for cell counting and viability assessment used in cell therapy, stem cell research, and bioprocessing; (3) Blood Safety Products (ADAM™ rWBC series) - residual white blood cell counters for blood bank quality control; (4) Stem Cell Products (ADAMII™ CD34) - fluorescence counters for hematopoietic stem cell enumeration; (5) T-Cell Analysis (ADAMII™ CD3/CD4/CD8) - immune cell counting kits; (6) ExTransfection™ - electroporation system for gene delivery; (7) JuLI™ Stage - live cell imaging system; and (8) Disposable Hemocytometers (C-Chip, S-Chip) - plastic counting chambers. The company also partnered with L'Oréal for Cell BioPrint technology used in Lancôme's longevity skincare products.
Differentiator
Problem solved
Functional benefit
Brands
- FREND: Microfluidic immunofluorescence analyzer system for in vitro diagnostics
- EVE
- ADAM
- C-chip
- JuLI
- Cell BioPrint
- ExTransfection
- BioTracer
Products and services
- FREND System Microfluidic immunofluorescence analyzer for rapid in vitro diagnostic testing using lab-on-a-chip technology for quantitative and qualitative detection of biomarkers, including thyroid, cardiac, infectious disease, COVID-19, and other analytes via disposable cartridges. Sold to clinical laboratories, hospitals, and point-of-care settings.
- FREND 2.0 Next-generation microfluidic immunofluorescence analyzer with enhanced features and performance for diagnostic testing, expanding the FREND platform's diagnostic capabilities.
- EVE HT High-Throughput Automated Cell Counter High-throughput automated trypan blue-based cell counter that measures up to 48 samples in 3 minutes using a disposable 48-channel plate, with optional 21CFR Part 11 compliance. Designed for cell therapy manufacturing and bioprocess monitoring.
- EVE HT FL High-Throughput Fluorescence Cell Counter High-throughput dual fluorescence cell counter using AO/DAPI channels for accurate viability assessment, measuring up to 48 samples in 3 minutes with 20µL sample required per test.
- EVE HT A26 Fully Automated Cell Counter Fully automated high-throughput cell counter for research and bioprocessing applications, showcased at SLAS Europe 2026 and Analytica 2026 exhibitions.
- EVE Plus Automated Cell Counter Automated cell counter marketed as the world's fastest cell counter, capable of counting cells within 1 second for research and cell culture applications.
- ADAM MC Plus Fluorescence Cell Counter Most accurate fluorescence cell counter utilizing PI staining technology for precise cell counting across applications including cell therapy and bioprocess QC.
- ADAM CellT Plus Fluorescence Cell Counter Enhanced automated fluorescence cell counter designed for cGMP-compliant environments with advanced features and 21CFR Part 11 support.
- ADAM MC2 Fluorescence Cell Counter Most accurate cell counter using fluorescence technology for various cell types including whole blood and PBMCs, used in cell therapy and stem cell workflows.
- ADAM CellT Fluorescence Cell Counter Automated fluorescence cell counter designed for cGMP production environments, compliant with 21CFR Part 11 regulatory requirements.
- ADAM rWBC2 Residual White Blood Cell Counter Residual White Blood Cell Counter for blood safety testing, ensuring quality control of blood products by detecting residual leukocytes in blood bank and cord blood applications.
- ADAM rWBC HT High-Throughput Residual WBC Counter High-throughput residual White Blood Cell Counter for automated blood safety quality control in blood component processing.
- ADAM rXBC Combined Residual WBC and RBC Counter Combined residual WBC and RBC counter for comprehensive blood component quality analysis in blood bank workflows.
- ADAMII CD34 Stem Cell Counter Fluorescence CD34 stem cell counter for hematopoietic stem cell enumeration in stem cell therapy and transplantation workflows.
- ADAMII CD3/CD4/CD8 Immune Cell Counting Kit Fluorescence kit for counting CD3+, CD3+CD4+, and CD3+CD8+ T lymphocytes using the ADAMII system for immune status monitoring in cell therapy and immunology research.
- ADAMII LS Image-Based Fluorescence Cell Analyzer Image-based fluorescence cell analyzer for research applications including viability, cell cycle, and apoptosis analysis.
- ADAMII CDx Bench-Top Immune Cell Counter Bench-top immune cell counter for CAR-T and immune cell therapy manufacturing and quality control (under development).
- ADAM SCC2 Somatic Cell Counter Automated Somatic Cell Counter for milk quality testing in dairy industry applications.
- ExTransfection Electroporation System Pipette-style electroporation system for efficient gene transfection, sold with disposable kits and accessories for various sample volumes for life science research.
- JuLI Stage Live Cell Imaging System Real-time live cell imaging system for continuous monitoring of cell cultures inside incubators for research and bioprocess workflows.
- FREND COVID-19 Test Cartridges COVID-19 diagnostic test cartridges for the FREND System including Neutralization Ab, Total Ab, Ag, Ag+FLU A&B, IgG/IgM Duo, and SP tests for clinical laboratories and point-of-care settings.
- FREND Thyroid Test Cartridges Quantitative tests for thyroid function including TSH, Free T4, Total T3, Free T3, and Thyroid Duo combo tests for the FREND System.
- FREND Cardiac Test Cartridges Cardiac biomarker tests including Cardiac Triple, BNP, Troponin I, and D-Dimer for cardiovascular diagnostics on the FREND System.
- FREND Other Diagnostic Test Cartridges Additional diagnostic tests for FREND including IL-6, PSA Plus, Testosterone, Vitamin D, hsCRP, PCT, FLU A&B, and TSH Neo (newborn screening).
- BioTracer Dengue Rapid Tests Rapid immunochromatographic tests for dengue detection including NS1 Ag, IgG/IgM, and Combo cards providing results in 15-20 minutes for clinical use.
- BioTracer Influenza A&B Rapid Tests Rapid tests for detection of Influenza A and B infections in card and strip formats for point-of-care diagnostics.
- C-Chip Disposable Hemocytometer Disposable plastic hemocytometer invented by NanoEntek in 2-channel and 4-channel formats that eliminates the need for washing and coverslips while maintaining counting accuracy. Consumable for cell counting workflows.
- S-Chip Disposable Sperm Counting Hemocytometer Disposable hemocytometer specifically designed for sperm counting with two chambers, precision capillary action, and 20µm chamber depth for andrology and fertility workflows.
- Cell BioPrint Biomarker Skin Diagnostic Technology (Licensing) Biomarker-based diagnostic technology licensed to cosmetics and personal care companies for personalized skin analysis based on biological age biomarkers. Licensed to L'Oréal for integration into Lancôme's Absolue Longevity MD skincare line.
Quantifiable outcome
- High-throughput cell counters can measure 48 samples in 3 minutes vs competitors taking ~210 minutes (70x faster)
- +4 more outcomes
Companies that use NanoEntek
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles3 records
NanoEntek technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
NanoEntek partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- L'Oréal (Lancôme)coreNanoEntek partnered with L'Oréal to provide Cell BioPrint diagnostic technology for Lancôme's Absolue Longevity MD skincare line launched March 27, 2026. The technology enables personalized skin analysis by assessing biological age biomarkers, integrated into Lancôme's five-product anti-aging skincare range priced $155-$175. This represents NanoEntek's first major entry into the cosmetics/beauty tech market.
- Timeline (Swiss Longevity Biotech)minorLancôme partnered with Swiss longevity biotech company Timeline to develop a new skincare line featuring Timeline's proprietary Mitopure molecule (pure form of Urolithin A). NanoEntek's Cell BioPrint technology was included alongside Timeline's Mitopure in Lancôme's launch, creating a combined longevity science and luxury beauty offering.
- QuictekminorQuictek is listed as a global partner/distributor in NanoEntek's worldwide partner network.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
NanoEntek competitors and assessment
Company assessmentDirect peers
- ChemoMetec: ChemoMetec manufactures the NucleoCounter family of automated cell counters using fluorescence-based viability assessment, the closest direct competitor to NanoEntek's EVE and ADAM product lines in cell therapy and bioprocessing QC.
- Logos Biosystems: Logos Biosystems produces the LUNA series of automated cell counters and the CELENA X high-content imager, directly competing with NanoEntek's fluorescence cell counters in research and cell therapy applications.
Broad incumbents
- Beckman Coulter Life Sciences: Beckman Coulter's Vi-Cell cell viability analyzer is a dominant installed instrument in bioprocessing QC and competes broadly with NanoEntek's ADAM and EVE product lines across pharma, biotech, and academic accounts.
- Thermo Fisher Scientific: Thermo Fisher sells the Countess and Invitrogen cell counting product lines alongside a full life sciences portfolio, representing a broad incumbent alternative to NanoEntek's automated counters and consumables.
- Bio-Rad Laboratories: Bio-Rad offers the TC20 automated cell counter and a broad life science research portfolio, overlapping with NanoEntek's research-focused cell counting instruments.
- Sysmex Corporation: Sysmex is a global leader in hematology and IVD analyzers including cell counting, directly overlapping with NanoEntek's FREND diagnostic platform and ADAM rWBC blood safety products.
- Roche Diagnostics: Roche operates a major IVD franchise spanning immunoassays, cardiac markers, and point-of-care diagnostics — overlapping with the clinical test menu of NanoEntek's FREND microfluidic analyzer.
Emerging players
- Sony Biotechnology (Sony Group): Sony Biotechnology's flow cytometry platforms (e.g., CGX10) compete with NanoEntek's fluorescence-based cell analysis tools in cell therapy manufacturing QC and immune cell characterization.
- Cytek Biosciences: Cytek's spectral flow cytometry platforms serve cell therapy QC and immune monitoring use cases that overlap with NanoEntek's ADAMII CD3/CD4/CD8 and CD34 fluorescence cell counters.
- ABM (Applied Biological Materials): ABM supplies cell culture reagents, transfection tools, and instruments to cell therapy researchers, providing an adjacent platform of competing tools alongside NanoEntek's electroporation (ExTransfection) and counter products.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
NanoEntek social profiles
Digital presenceNanoEntek compliance and trust
Trust signalCompliance1 record
NanoEntek financial estimates
Financial estimateRevenue estimate
Valuation estimate
NanoEntek leadership team
Management profileNumber of profiles
NanoEntek subsidiaries and ownership
Company hierarchySubsidiaries3 records
NanoEntek funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NanoEntek M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NanoEntek
What does NanoEntek do?
NanoEntek designs and manufactures lab-on-a-chip instruments that combine MEMS and micro-fluidics for biomedical analysis. The company sells automated cell counters (EVE and ADAM series), a microfluidic immunofluorescence diagnostic analyzer (FREND), rapid diagnostic test kits (BioTracer), disposable plastic hemocytometers (C-Chip, S-Chip), live cell imaging systems (JuLI), and an electroporation system (ExTransfection), used by cell therapy manufacturers, blood banks, and clinical laboratories. The Cell BioPrint biomarker-based skin diagnostic technology was developed and licensed to L'Oréal for use in Lancôme's Absolue Longevity MD skincare line.
Is NanoEntek a public or private company?
NanoEntek is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NanoEntek founded?
NanoEntek was founded in 2000. It employs 51 to 100 people.
Where is NanoEntek based?
NanoEntek is headquartered in Seoul, South Korea, in the Asia region.
How does NanoEntek make money?
Four revenue lines are on record. Automated Cell Counters and Analyzers are the primary driver. The others are consumables and Reagents, in Vitro Diagnostic Tests and licensing/Technology Partnerships.
Who are NanoEntek's main competitors?
Direct peers on record are ChemoMetec and Logos Biosystems. Broad incumbents are Beckman Coulter Life Sciences, Thermo Fisher Scientific, Bio-Rad Laboratories, Sysmex Corporation and Roche Diagnostics. Emerging players are Sony Biotechnology (Sony Group), Cytek Biosciences and ABM (Applied Biological Materials).
Does NanoEntek have an API?
No public API is recorded for NanoEntek.
What industry is NanoEntek in?
NanoEntek's product category is Life Science Instrumentation. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 334516 and its SIC code is 3826.